A Phase I Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)/Prolymphocytic Leukemia (PLL).

Trial Profile

A Phase I Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)/Prolymphocytic Leukemia (PLL).

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Apr 2017

At a glance

  • Drugs Carfilzomib (Primary)
  • Indications B cell prolymphocytic leukaemia; Chronic lymphocytic leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 06 May 2016 Status changed from active, no longer recruiting to completed.
    • 09 Apr 2014 Planned end date changed from 1 Jun 2014 to 1 Oct 2014 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top